Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer-Reference-Cited by-同舟云学术

Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer

Published:2023-07 Issue: Volume:122-123 Page:108368
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Hoffman S.L.V.,Mixdorf J.C.,Kwon O.,Johnson T.R.,Makvandi M.,Lee H.,Aluicio-Sarduy E.,Barnhart T.E.,Jeffery J.J.,Patankar M.S.,Engle J.W.,Bednarz B.P.,Ellison P.A.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference61 articles.

1. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023

2. Cancer statistics, 2002;Jemal;CA Cancer J Clin,2002

3. Front-line therapy of advanced epithelial ovarian cancer: standard treatment;Marth;Ann Oncol,2017

4. Platinum-based drugs for cancer therapy and anti-tumor strategies;Zhang;Theranostics,2022

5. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer;Colombo;Crit Rev Oncol Hematol,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes;Expert Review of Anticancer Therapy;2024-09-03

2. Monte Carlo-Based Nanoscale Dosimetry Holds Promise for Radiopharmaceutical Therapy Involving Auger Electron Emitters;Cancers;2024-06-26

3. PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview;Current Issues in Molecular Biology;2024-03-31

4. Advances in Radioligand Theranostics in Oncology;Molecular Diagnosis & Therapy;2024-03-31